Post-transaction, Clarivate will operate as a subscription-first provider of intelligence, workflow software, and tech-enabled services within A&G and IP, leveraging shared platforms and content assets.

Clarivate anticipates a non-cash goodwill impairment of about $225–$250 million related to LS&H, based on the sale price, not affecting full-year outlook metrics.

Clarivate will receive $500 million in cash at closing, $25 million later under a transition services agreement, and a $75 million seller note, with total potential liquidity of $600 million to reduce debt and strengthen financial flexibility.

LS&H delivers data assets and analytics across the drug and device lifecycles, which Altaris intends to continue investing in and expanding.

Clarivate agreed to sell its Life Sciences & Healthcare segment to Altaris for $600 million, signaling a strategic pivot toward Academ ia & Government and Intellectual Property businesses.

The move is designed to strengthen Clarivate’s financial profile by improving the revenue mix, reducing capital intensity, expanding adjusted EBITDA margins, and enabling a more focused, scalable portfolio.

Henry Levy, president of LS&H, said Altaris will back continued growth and investment while keeping a clear focus on customer impact.

LS&H provides data, analytics, and lifecycle expertise for drug and device companies from R&D through market access.

The transaction is expected to close by year-end, subject to regulatory approvals, with LS&H classified as discontinued operations starting in Q3 2026 and a fuller full-year outlook after closing.

The sale supports Clarivate’s Value Creation Plan by optimizing the portfolio, improving sales execution, accelerating innovation, and unlocking shareholder value through a stronger financial position.

Altaris, a healthcare-focused investor, aims to invest in and grow LS&H under its ownership as part of Clarivate’s portfolio optimization.

The deal will translate into a more focused portfolio while Clarivate accelerates debt reduction and simplifies its structure ahead of the closing.